Catalyst Capital Advisors LLC increased its holdings in shares of Amarin Co. plc (NASDAQ:AMRN) by 45.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 412,000 shares of the biopharmaceutical company’s stock after purchasing an additional 128,000 shares during the period. Catalyst Capital Advisors LLC owned approximately 0.12% of Amarin worth $8,833,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in AMRN. Atria Investments LLC bought a new position in Amarin in the second quarter worth approximately $166,000. Valeo Financial Advisors LLC boosted its holdings in Amarin by 23,330.0% in the third quarter. Valeo Financial Advisors LLC now owns 2,343 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 2,333 shares in the last quarter. Rhenman & Partners Asset Management AB boosted its holdings in Amarin by 14.0% in the third quarter. Rhenman & Partners Asset Management AB now owns 400,000 shares of the biopharmaceutical company’s stock worth $6,064,000 after acquiring an additional 49,200 shares in the last quarter. Ogorek Anthony Joseph NY ADV boosted its holdings in Amarin by 12.1% in the third quarter. Ogorek Anthony Joseph NY ADV now owns 19,960 shares of the biopharmaceutical company’s stock worth $302,000 after acquiring an additional 2,160 shares in the last quarter. Finally, Wedbush Securities Inc. bought a new position in Amarin in the third quarter worth approximately $159,000. 52.87% of the stock is owned by institutional investors and hedge funds.
In other news, CEO John F. Thero sold 274,454 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $20.91, for a total value of $5,738,833.14. 2.75% of the stock is owned by company insiders.
AMRN stock opened at $18.18 on Thursday. Amarin Co. plc has a twelve month low of $13.76 and a twelve month high of $26.12. The company has a quick ratio of 3.45, a current ratio of 3.69 and a debt-to-equity ratio of 0.02. The stock’s 50 day moving average is $19.81 and its 200-day moving average is $18.24. The firm has a market capitalization of $6.40 billion, a PE ratio of -90.90 and a beta of 1.07.
AMRN has been the topic of several recent research reports. Stifel Nicolaus reiterated a “hold” rating on shares of Amarin in a report on Tuesday, January 7th. Aegis initiated coverage on Amarin in a report on Thursday, October 31st. They issued a “buy” rating and a $23.00 price target on the stock. ValuEngine upgraded Amarin from a “hold” rating to a “buy” rating in a report on Monday, February 3rd. Zacks Investment Research lowered Amarin from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, HC Wainwright restated a “buy” rating and issued a $51.00 target price on shares of Amarin in a report on Thursday, January 9th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $27.62.
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.